
    
      OBJECTIVES: I. Determine the feasibility and tolerability of administering amifostine by
      intravenous infusion over 5 minutes in cancer patients undergoing chemotherapy.

      OUTLINE: This is an open label, controlled study. Patients receive intravenous amifostine
      over 5 minutes 30 minutes prior to chemotherapy. Patients are followed for one month post
      treatment.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    
  